News Detail
New Delhi, 22 Sept 2023: The Subject Expert Committee (SEC) on vaccines, which reviews proposals and advice the Drugs Controller General (India) (DCGI) in matters for biologicals and post approval change proposals, has recommended to grant permission to Gujarat-based Cadila Pharm......
View Details
Source : Pharmabiz
Subject Expert Committee
SEC
DCGI
biological
Cadila Pharmaceuticals
Varicella-Zoster Virus
VZV vaccine
New Drugs and Clinical Trials Rules
2019
WHO
Varicella
chickenpox
varicella-zoster virus
herpesvirus
Oka VZV
MMRV
ThRabis
Related News
- Innovative Cancer Treatment may sometimes cause Cancer, US FDA. Says (01-12-2023)
- New NMC logo facing the wrath of Medical fraternity (01-12-2023)
- MP: Local pharma firms record an upside in overseas orders (01-12-2023)
- Karnataka’s draft biotech policy draws up efforts to chalk out transformative growth trajectory (01-12-2023)
- India so far approved 15 vaccines and five booster doses: CDSCO (01-12-2023)
- US FDA flags data manipulation, management failures in warning letter to Intas on import alert (01-12-2023)
- PCI to Pharmacy Council of India to launch revamped "DIGI-PHARMed" application today (01-12-2023)
- Ahmedabad Crime Branch arrested two people with banned tabs, intoxicating syrup (01-12-2023)
- How Patanjali rode on the shoulders of Big Media (30-11-2023)
- 5 Dead, 2 Hospitalized after Consuming Ayurvedic 'Kalmeghasav' in Gujarat (30-11-2023)